New Opportunities to Improve Management of Patients with or at High Risk of ASCVD Events

New Opportunities to Improve Management of Patients with or at High Risk of ASCVD Events
RestartResume
To register for this meeting, click on the ENROLL button. Login using your ReachMD credentials, or create a new Medtelligence / ReachMD account. ...more

Available credits: 2.00

  • Meeting date: 11 April, 2019
  • Meeting time: 06:30 PM - 09:00 PM EDT
  • Meeting location: Philadelphia 201 Hotel
  • Meeting address: 201 N. 17th Street, Philadelphia, Pennsylvania, United States
  • Overview

    This timely and engaging CME-certified symposium will offer in-depth coverage of important clinical issues and data. Featuring a faculty of leading experts in the management of atherosclerotic cardiovascular disease (ASCVD), the program will utilize case-based learning in a highly interactive format to optimize clinical strategies.

    Agenda Topics Include

    • Update on Determining Risk Status in ASCVD
    • New Approaches to the Management of Patients at High Risk of CVD Events
    • Managing Residual Risk Beyond LDL-C Lowering Therapy
    • Practical Considerations to Manage Residual Risk
    • Case Simulations on Primary and Secondary Prevention of ASCVD Events
  • Program Schedule

     

    6:30 pm–7:00 pm             

    Registration & Dinner

     

     

     

     

    7:00 pm–7:10 pm

    Welcome, Introductions, Program Overview, and Pre-Activity Test Questions

     

     

     

     

    7:10 pm–7:25 pm

    Update on Determining Risk Status in ASCVD

    • Who is at high risk for CVD events
    • AHA cholesterol guidelines approach to diagnosis – what’s new
    • Screening and diagnosis, including fasting and nonfasting blood samples, non-HDL-C assessment, CAC
    • Risk assessment based on AHA guidelines

     

     

     

     

    7:25 pm–7:30 pm

    Discussion and Question & Answers

     

     

     

     

    7:30 pm–7:45 pm

    New Approaches to the Management of Patients at High-Risk of CVD Events

    • Role of lifestyle modification; AHA’s lifelong lifestyle guideline
    • LDL-C lowering with statin intensification
    • LDL-C lowering beyond statins: ezetimibe and PCSK9 inhibitors
    • AHA guidelines for primary and secondary prevention of ASCVD events

     

     

     

     

    7:45 pm–7:50 pm

    Discussion and Question & Answers

     

     

     

     

    7:50 pm–8:15 pm

    Managing Residual Risk Beyond LDL-C Lowering Therapy

    • Pathologic mechanisms contributing to ASCVD: TG-RL, inflammation, etc
    • Genetic evidence for TG-RL causal effects
    • Limited and poor evidence of outcomes studies on fibrates and niacin
    • Limited and poor evidence of outcomes studies of EPA/DHA outcomes studies; role of drug, dose, and patient population selection
    • JELIS and REDUCE-IT outcomes trials
    • REDUCE-IT outcomes points to pleiotropic effect of EPA
    • Known effects of EPA to reduce MOA burden in ASCVD
    • Other opportunities to reduce ASCVD events: Inflammation proof-of-concert (CANTOS and CIRT) Metabolic studies (GLP-1s and SGLT-2s), anticoagulation studies (COMPASS)

     

     

     

     

    8:15 pm–8:20 pm

    Discussion and Question & Answers

     

     

     

     

    8:20 pm–8:35 pm

    Practical Considerations to Manage Residual Risk

    • Personalized approach; assessment of how much risk and what is underlying risk
    • Pharmacologic management algorithms beyond statins to prevent events
    • Use of EPA to manage residual risk: drug, dose, patient selection
    • Managing risk pragmatically for success
    • Dosing considerations/contraindication of dietary supplements

     

     

     

     

    8:35 pm–8:40 pm

    Discussion and Question & Answers

     

     

     

     

    8:40 pm–8:55 pm

    Case Simulations on Primary and Secondary Prevention of ASCVD Events

    • Two cases with multiple parts, one primary prevention, one secondary prevention, including diabetes/obesity as a co-morbidity. ARS questions will be used for interactive learning

     

     

     

     

    8:50 pm–9:00 pm

    Post-activity test questions, Closing Comments, and Adjourn

     

     

     

     

     

  • Target Audience

    This course is designed to meet the continuing medical education needs of the Internal Medicine and Primary Care Physicians and allied health professionals who treat patients with, or at high risk of, ASCVD.

  • Providers

    Jointly provided by TOPEC and Medtelligence.

       

  • Commercial Support

    This activity is supported by independent educational grants from Amarin Pharma, Inc.

Facebook Comments

Sign-up for the Medtelligence's newsletters.
Comprehensive Cardiology Education.

Better education for a better you.

* Required
Optional
Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free